Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Medical Decision Making
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Djulbegovic, B.
Right arrow Articles by Herzig, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Djulbegovic, B.
Right arrow Articles by Herzig, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Comparison of Different Treatment strategies for Diffuse Large-cell Lymphomas

A Decision Analysis

Benjamin Djulbegovic, MD, PhD

James Hollenberg, MD

Thomas M. Woodcock, MD

Roger Herzig, MD

There are more than 20 drug combinations in use for the treatment of diffuse large-cell non- Hodgkin's lymphoma (NHL). New treatments have been developed without prior comparison in clinical trials. The authors devised a Markov-process model to compare the efficacy of a first-generation combination chemotherapy regimen (CHOP) with that of a third-generation regimen (MACOP-B) using currently available data. For a typical 57-year-old male patient, life expectancy with MACOP-B was 12.1 years, compared with 8.3 years with CHOP. The remission rate after initial treatment and the functional status after the first remission is achieved were the most important determinants of life expectancy. It was still possible for CHOP to become better strategy provided that the initial remission rate with MACOP-B were lower than 50% or that functional status after remission was achieved were less than 66%. The analysis suggests that the most effective therapeutic regimen for diffuse large-cell lymphoma must not only result in a high remission rate but also cause minimal late sequelae. These two parameters were incorporated into the nomogram, which can serve as a basis for comparison of the efficacy of any chemotherapeutic regimen in non-Hodgkin's lymphoma. Key words: decision analysis; Markov model; non-Hodgkin's lymphoma; chemotherapy. (Med Decis Making 1991;11:1-8)

Medical Decision Making, Vol. 11, No. 1, 1-8 (1991)
DOI: 10.1177/0272989X9101100101
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
C. S. Cutler, S. J. Lee, P. Greenberg, H. J. Deeg, W. S. Perez, C. Anasetti, B. J. Bolwell, M. S. Cairo, R. P. Gale, J. P. Klein, et al.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
Blood, July 15, 2004; 104(2): 579 - 585.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
B. E. Hillner, T. J. Smith, and C. E. Desch
Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer: Estimates Using Decision Analysis While Awaiting Clinical Trial Results
JAMA, April 15, 1992; 267(15): 2055 - 2061.
[Abstract] [PDF]